lystn

In the first episode of 2024, hosts Drs. Temara Hajjat and Jason Silverman talk to Dr. William Balistreri about some of the new developments in the hepatology field over the past year. 

This episode is eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!

Links for this episode:

1. Acute hepatitis of unknown etiology in children 
2. Gilbert's Syndrome
3. Emerging therapy for A-1-AT deficiency - Fazirsiran (1, 2 and 3)
4. Matrix metalloproteinase-7 (MMP-7) and biliary atresia
5. Methotrexate and the risk of liver disease (1, 2, 3, 4, and 5)
6. Warning from the FDA about the use of selective androgen receptor modulators (SARMS) among teens and young adults (also here and here)

Learning Objectives:

1. Learning the new and upcoming studies in the hepatology field.
2. Reviewing the hepatology medications that have been FDA-approved for children.
3. Learning the new technologies to treat and detect liver conditions in children. 

Produced by: Temara Hajjat

As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.

Check out our merch website!

Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes.

Click here to support the show.